Table 3 Changes of clinical stage of the ITT population (n = 231) before (cStage) and after (ycStage) neoadjuvant treatment.
Characteristic | Chemotherapy | Immunochemotherapy | ||||
|---|---|---|---|---|---|---|
cStage, | ycStage, | P-value | cStage, | ycStage, | P-value | |
n = 78 | n = 78 | n = 153 | n = 153 | |||
T stage, n (%) | 0.009 | < 0.001 | ||||
T0 | 0 (0.0) | 1 (1.3) | 0 (0.0) | 0 (0.0) | ||
T1a | 0 (0.0) | 1 (1.3) | 0 (0.0) | 13 (8.5) | ||
T1b | 3 (3.8) | 13 (16.7) | 6 (3.9) | 38 (24.8) | ||
T1c | 11 (14.1) | 23 (29.5) | 15 (9.8) | 42 (27.5) | ||
T2a | 14 (17.9) | 12 (15.4) | 31 (20.3) | 23 (15.0) | ||
T2b | 14 (17.9) | 8 (10.3) | 35 (22.9) | 19 (12.4) | ||
T3 | 21 (26.9) | 12 (15.4) | 36 (23.5) | 13 (8.5) | ||
T4 | 15 (19.2) | 8 (10.3) | 30 (19.6) | 5 (3.3) | ||
N stage, n (%) | 0.856 | 0.563 | ||||
N0 | 3 (3.8) | 5 (6.4) | 8 (5.2) | 11 (7.2) | ||
N1 | 12 (15.4) | 13 (16.7) | 26 (17.0) | 33 (21.6) | ||
N2 | 60 (76.9) | 58 (74.4) | 117 (76.5) | 106 (69.3) | ||
N3 | 3 (3.8) | 2 (2.6) | 2 (1.3) | 3 (2.0) | ||
Stage, n (%) | 0.046 | < 0.001 | ||||
0 | 0 (0.0) | 1 (1.3) | 0 (0.0) | 0 (0.0) | ||
IA | 0 (0.0) | 4 (5.1) | 0 (0.0) | 5 (3.3) | ||
IB | 1 (1.3) | 0 (0.0) | 4 (2.6) | 3 (2.0) | ||
IC | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | ||
IIA | 1 (1.3) | 0 (0.0) | 2 (1.3) | 2 (1.3) | ||
IIB | 9 (11.5) | 11 (14.1) | 17 (11.1) | 33 (21.6) | ||
IIIA | 32 (41.0) | 42 (53.8) | 75 (49.0) | 91 (59.5) | ||
IIIB | 35 (44.9) | 19 (24.4) | 55 (35.9) | 19 (12.4) | ||
IVA | 0 (0.0) | 1 (1.3) | 0 (0.0) | 0 (0.0) | ||
